Adaptimmune's CEO discusses last night's FDA accelerated approval of TECELRA, a TCR-based engineered cell therapy for synovial sarcoma
- blonca9
- Aug 2, 2024
- 1 min read
Adrian Rawcliffe describes how the treatment works, the expected rollout and cost, and what this means for TCR therapies going forward.